Completed NA INTERVENTIONAL 2-arm NCT00612508

Hormonal Contraception and Vaginal Health

The Effects of Oral vs. Intravaginal Hormonal Contraception on Vaginal Health

Sponsor: Oregon Clinical and Translational Research Institute

Conditions Contraceptive Usage Vaginal Epithelial Disruption

Interventions Desogen (ethinyl estradiol and desogestrel) NuvaRing (ethinyl estradiol and etonogestrel)

Updated 7 times since 2017 Last updated: Oct 9, 2012 Started: May 31, 2007 Primary completion: May 31, 2008 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Contraceptive Usage and Vaginal Epithelial Disruption, this trial is completed. The trial is conducted by Oregon Clinical and Translational Research Institute and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Dec 2021 — Jul 2024 [monthly]

Completed NA
Jan 2021 — Dec 2021 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oregon Clinical and Translational Research Institute
Oregon Health and Science University

Data source: Oregon Health and Science University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Portland, United States